The US Food and Drug Administration (FDA) has accepted Merck's biologics license application (BLA) for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet. The immunotherapy tablet is an investigational sublingual dissolvable tablet designed to help treat the underlying cause of allergic rhinitis by generating an immune response to help protect against the targeted allergen. Merck has partnered with ALK-Abello to develop its sublingual allergy immunotherapy tablets for ragweed pollen, timothy grass pollen and house dust mite in North America.
http://www.pharmabiz.com/NewsDetails.aspx?aid=75270&sid=2
Subscribe to:
Post Comments (Atom)
Mother and daughter getting allergy skin tests. Click on the photo to see a You Tube interview with another parent and child.
No comments:
Post a Comment